FDC Limited (NSE:FDC)
India
· Delayed Price · Currency is INR | Market Cap | 71.64B |
| Revenue (ttm) | 20.72B |
| Net Income (ttm) | 3.17B |
| Shares Out | n/a |
| EPS (ttm) | 19.46 |
| PE Ratio | 22.63 |
| Forward PE | n/a |
| Dividend | 5.00 (1.06%) |
| Ex-Dividend Date | Nov 22, 2024 |
| Volume | 124,880 |
| Average Volume | 73,827 |
| Open | 459.90 |
| Previous Close | 460.60 |
| Day's Range | 448.55 - 464.40 |
| 52-Week Range | 405.00 - 658.85 |
| Beta | 0.28 |
| RSI | 31.01 |
| Earnings Date | Feb 7, 2025 |
About FDC Limited
FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmic, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, and analgesics; and anti-oxidants, balanced energy and protein drinks, and vitamins and nutraceuticals, as well as various active pharmaceutical ingredients. It provides its products under the Zifi, Zefu, Zocon, Amodep-AT... [Read more]
Financial Performance
In 2023, FDC Limited's revenue was 19.43 billion, an increase of 8.92% compared to the previous year's 17.84 billion. Earnings were 3.05 billion, an increase of 57.30%.
Financial StatementsNews
FDC receives US FDA approval for Cefixime 400 mg tablets
FDC Limited has recently informed exchanges that the company has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Cefixime 4...
FDC shares surge 11%, leading gains in BSE Healthcare index
Shares of FDC Limited surged by 11.22% today, reaching ₹642.95, making it one of the top performers in the BSE Healthcare Index. The index itself was up 1.0%, with other top gainers including Hikal Ch...